Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade

Rothschild raised its price target to $81 from $40 but said the stock still has 46% downside and little near-term upside.

Summary by MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade

5 Articles

The Motley FoolThe Motley Fool
Lean Left

Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?

The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.

·Alexandria, United States
Read Full Article
Seeking AlphaSeeking Alpha
Lean Right

Moderna stock slips as Rothschild downgrades (MRNA:NASDAQ)

Moderna (MRNA) stock slides as Rothschild & Co. Redburn downgrades to Sell, arguing that the firm's recent rally after cancer vaccine data was overdone. Read more here.

·Ra'anana, Israel
Read Full Article
MarketBeatMarketBeat
Reposted by
thecerbatgem.comthecerbatgem.com
Center

Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade

Moderna (NASDAQ:MRNA) Shares Gap Down on Analyst Downgrade

·Sioux Falls, United States
Read Full Article
CNBCCNBC
Lean Left

Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says

The research firm downgraded the biotechnology stock to sell from neutral.

·Englewood Cliffs, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left
50% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

CNBC broke the news in Englewood Cliffs, United States on Thursday, September 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Moderna icon

Moderna

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal